Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis

   Status unknown · Not applicable · Carotid Artery Stenosis

   NCT02657707 · Microvention, Inc. · 10 U.S. investigators

   $95,498research payments

2. A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

   Active, not recruiting · Phase 1, Phase 2 · Leukemia, Myeloid, Acute

   NCT02677922 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

   $94,624research payments

3. Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

   Terminated · Phase 2 · Osteosarcoma

   NCT06341712 · Ipsen Innovation · 4 U.S. investigators

   $93,345research payments

4. A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

   Completed · Phase 1 · Healthy Volunteers

   NCT06850051 · Sanofi Pasteur Inc. · 0 U.S. investigators

   $93,100research payments

5. Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

   Recruiting · Phase 2 · Brain Metastases

   NCT05554302 · Blue Earth Diagnostics · 1 U.S. investigator

   $92,997research payments

6. A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

   Active, not recruiting · Phase 1 · Systemic Lupus Erythematosus

   NCT05869955 · E.r. Squibb & Sons, L.l.c. · 7 U.S. investigators

   $92,550research payments

7. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

   Recruiting · Phase 3 · Esophageal Squamous Cell Carcinoma

   NCT06644781 · Daiichi Sankyo Inc. · 7 U.S. investigators

   $91,987research payments

8. Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

   Completed · Phase 2 · Moderate-to-Severe Atopic Dermatitis

   NCT04921345 · Galderma Laboratories, L.P. · 11 U.S. investigators

   $91,145research payments

9. CERAMENT™| Bone Void Filler Device Registry

   Recruiting · Orthopedic Disorder

   NCT04244942 · Bone Support Ab · 8 U.S. investigators

   $90,639research payments

10. A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

    Active, not recruiting · Phase 1 · Myeloproliferative Neoplasm

    NCT04041050 · AbbVie Inc. · 6 U.S. investigators

    $90,392research payments

11. Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

    Active, not recruiting · Phase 1 · Non-hodgkin Lymphoma

    NCT05206357 · AbbVie Inc. · 8 U.S. investigators

    $89,591research payments

12. Phase 1 Study of Oral TP-1454

    Completed · Phase 1 · Advanced Solid Tumor

    NCT04328740 · Sumitomo Pharma America, Inc. · 7 U.S. investigators

    $89,237research payments

13. Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

    Recruiting · Phase 2 · Atrial Fibrillation (AF)

    NCT07175428 · Regeneron Pharmaceuticals, Inc. · 4 U.S. investigators

    $88,889research payments

14. A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

    Terminated · Phase 2 · Breast Cancer

    NCT03248492 · Daiichi Sankyo Inc. · 5 U.S. investigators

    $88,598research payments

15. A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

    Completed · Phase 3 · Schizophrenia

    NCT05628103 · Sumitomo Pharma America, Inc. · 8 U.S. investigators

    $88,165research payments

16. Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Recruiting · Phase 1 · Multiple Myeloma

    NCT06896916 · AbbVie Inc. · 3 U.S. investigators

    $87,039research payments

17. A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

    Active, not recruiting · Phase 1, Phase 2 · NSCLC

    NCT04077099 · Regeneron Pharmaceuticals, Inc. · 8 U.S. investigators

    $86,778research payments

18. CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

    Terminated · Phase 2, Phase 3 · Melanoma

    NCT04695977 · Regeneron Pharmaceuticals, Inc. · 4 U.S. investigators

    $86,575research payments

19. Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

    Completed · Phase 3 · Non-small Cell Lung Cancer

    NCT03409614 · Regeneron Pharmaceuticals, Inc. · 8 U.S. investigators

    $86,230research payments

20. A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

    Completed · Phase 3 · Psoriasis

    NCT04435600 · AbbVie Inc. · 8 U.S. investigators

    $85,380research payments

21. A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

    Recruiting · Phase 2 · Major Depressive Disorder

    NCT07276997 · AbbVie Inc. · 6 U.S. investigators

    $84,571research payments

22. A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

    Active, not recruiting · Alzheimer Disease

    NCT02951598 · Eli Lilly and Company · 1 U.S. investigator

    $84,525research payments

23. A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

    Terminated · Phase 1, Phase 2 · Diffuse Large B-cell Lymphoma (DLBCL)

    NCT02875548 · Epizyme, Inc. · 8 U.S. investigators

    $84,346research payments

24. Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

    Completed · Phase 2 · Advanced Colorectal Cancer

    NCT04744831 · Daiichi Sankyo Inc. · 2 U.S. investigators

    $83,338research payments

25. Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

    Active, not recruiting · Phase 2 · Peripheral Nerve Sheath Tumor

    NCT04917042 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $83,100research payments

26. Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

    Completed · Phase 3 · Irritable Bowel Syndrome With Constipation

    NCT04166058 · AbbVie Inc. · 10 U.S. investigators

    $82,885research payments

27. A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

    Completed · Phase 3 · Atopic Dermatitis

    NCT03607422 · AbbVie Inc. · 17 U.S. investigators

    $82,793research payments

28. Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

    Completed · Phase 2 · Leukemia

    NCT02910583 · AbbVie Inc. · 3 U.S. investigators

    $82,750research payments

29. Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

    Recruiting · Phase 2 · Recurrent Transformed Chronic Lymphocytic Leukemia

    NCT05873712 · Beigene USA, Inc. · 1 U.S. investigator

    $82,297research payments

30. A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)

    Active, not recruiting · Not applicable · Lumbar Spinal Stenosis

    NCT04192591 · Boston Scientific Corporation · 13 U.S. investigators

    $82,143research payments

31. A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

    Withdrawn · Phase 4 · Bladder Cancer

    NCT06390111 · Ferring Pharmaceuticals As · 4 U.S. investigators

    $82,067research payments

32. A Retrospective Study to Characterize Participants With Propionic Acidemia

    Recruiting · Propionic Acidemia

    NCT05769621 · ModernaTX, Inc. · 7 U.S. investigators

    $81,639research payments

33. Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

    Terminated · Phase 3 · Influenza Immunization

    NCT05513391 · Sanofi Pasteur Inc. · 2 U.S. investigators

    $81,380research payments

34. A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

    Active, not recruiting · Phase 3 · Myelodysplastic Syndromes

    NCT03682536 · E.r. Squibb & Sons, L.l.c. · 8 U.S. investigators

    $81,137research payments

35. A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

    Withdrawn · Phase 3 · Autosomal Recessive Polycystic Kidney Disease (ARPKD)

    NCT04786574 · Otsuka Pharmaceutical Development & Commercialization, Inc. · 6 U.S. investigators

    $80,736research payments

36. ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

    Terminated · Phase 1, Phase 2 · Multiple Myeloma

    NCT01997840 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $80,694research payments

37. Afrezza® INHALE-1 Study in Pediatrics

    Completed · Phase 3 · Diabetes Mellitus, Type 1

    NCT04974528 · Mannkind Corporation · 0 U.S. investigators

    $80,574research payments

38. Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

    Active, not recruiting · Phase 1 · Diffuse Large B-Cell Lymphoma

    NCT04850495 · Beigene, Ltd. · 1 U.S. investigator

    $80,254research payments

39. VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)

    Completed · Not applicable · High-risk Percutaneous Coronary Intervention

    NCT06132568 · Boston Scientific Corporation · 4 U.S. investigators

    $80,032research payments

40. Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

    Completed · Phase 4 · Psoriatic Arthritis

    NCT03419650 · Mallinckrodt Hospital Products Inc. · 1 U.S. investigator

    $80,000research payments

41. A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

    Recruiting · Phase 3 · Advanced Cancer

    NCT06174987 · Daiichi Sankyo Inc. · 2 U.S. investigators

    $79,908research payments

42. GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

    Terminated · Not applicable · Migraine

    NCT04100135 · W. L. Gore & Associates, Inc. · 4 U.S. investigators

    $79,782research payments

43. A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants

    Recruiting · Phase 1 · Healthy Volunteer

    NCT07219030 · AbbVie Inc. · 2 U.S. investigators

    $79,569research payments

44. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

    Recruiting · Phase 3 · Bipolar Disorder Type I With Mania or Mania With Mixed Features

    NCT06951711 · E.r. Squibb & Sons, L.l.c. · 20 U.S. investigators

    $79,515research payments

45. Mucopolysaccharidosis VII Disease Monitoring Program

    Recruiting · Mucopolysaccharidosis VII

    NCT03604835 · Ultragenyx Pharmaceutical Inc. · 6 U.S. investigators

    $79,380research payments

46. Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

    Recruiting · Phase 2 · Prostate Adenocarcinoma

    NCT07025369 · Blue Earth Diagnostics · 1 U.S. investigator

    $79,274research payments

47. Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

    Completed · Phase 1 · Human Immunodeficiency Virus (HIV)

    NCT04554966 · AbbVie Inc. · 2 U.S. investigators

    $78,984research payments

48. A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

    Completed · Phase 3 · SARS-CoV-2

    NCT06097273 · ModernaTX, Inc. · 15 U.S. investigators

    $78,673research payments

49. A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

    Completed · Phase 2 · Psoriasis

    NCT05730725 · E.r. Squibb & Sons, L.l.c. · 4 U.S. investigators

    $78,651research payments

50. REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

    Terminated · Phase 1, Phase 2 · Relapsed Solid Tumor

    NCT03690869 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $78,470research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.